Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
Saint Joseph Regional Medical Center
mi
from
South Bend, IN
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
Saint Joseph Regional Medical Center
mi
from
South Bend, IN
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
South Bend Clinic
mi
from
South Bend, IN
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
South Bend Clinic
mi
from
South Bend, IN
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
Lakeside Cancer Specialists, PLLC
mi
from
Saint Joseph, MI
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
Lakeside Cancer Specialists, PLLC
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
St. Joseph, MI
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
St. Joseph, MI
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
Ellis Fischel Cancer Center at University of Missouri - Columbia
mi
from
Columbia, MO
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
Ellis Fischel Cancer Center at University of Missouri - Columbia
mi
from
Columbia, MO
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
Cancer Resource Center - Lincoln
mi
from
Lincoln, NE
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
Cancer Resource Center - Lincoln
mi
from
Lincoln, NE
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
Immanuel Medical Center
mi
from
Omaha, NE
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
Immanuel Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
Alegent Health Cancer Center at Bergan Mercy Medical Center
mi
from
Omaha, NE
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
Alegent Health Cancer Center at Bergan Mercy Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
Creighton University Medical Center
mi
from
Omaha, NE
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
Creighton University Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care
mi
from
Concord, NH
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care
mi
from
Concord, NH
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
New Hampshire Oncology - Hematology, PA - Hooksett
mi
from
Hooksett, NH
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
New Hampshire Oncology - Hematology, PA - Hooksett
mi
from
Hooksett, NH
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
Lakes Region General Hospital
mi
from
Laconia, NH
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
Lakes Region General Hospital
mi
from
Laconia, NH
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
CCOP - Hematology-Oncology Associates of Central New York
mi
from
East Syracuse, NY
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
CCOP - Hematology-Oncology Associates of Central New York
mi
from
East Syracuse, NY
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
Kinston Medical Specialists
mi
from
Kinston, NC
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
Kinston Medical Specialists
mi
from
Kinston, NC
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
Rex Cancer Center at Rex Hospital
mi
from
Raleigh, NC
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
Rex Cancer Center at Rex Hospital
mi
from
Raleigh, NC
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
Iredell Memorial Hospital
mi
from
Statesville, NC
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
Iredell Memorial Hospital
mi
from
Statesville, NC
Click here to add this to my saved trials
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated:  11/13/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab
A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
Status: Enrolling
Updated: 11/13/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated:  11/13/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated: 11/13/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated:  11/13/2015
The University of California, San Diego
mi
from
La Jolla, CA
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated: 11/13/2015
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated:  11/13/2015
UCLA Med-Hematology & Oncology
mi
from
Los Angeles, CA
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated: 11/13/2015
UCLA Med-Hematology & Oncology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated:  11/13/2015
University of California at San Francisco
mi
from
San Francisco, CA
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated: 11/13/2015
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated:  11/13/2015
University of Colorado Cancer Center
mi
from
Aurora, CO
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated: 11/13/2015
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated:  11/13/2015
Christiana Care Health System
mi
from
Newark, DE
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated: 11/13/2015
Christiana Care Health System
mi
from
Newark, DE
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated:  11/13/2015
Emory University School of Medicine
mi
from
Atlanta, GA
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated: 11/13/2015
Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated:  11/13/2015
University of Chicago Medical Center
mi
from
Chicago, IL
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated: 11/13/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated:  11/13/2015
Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated: 11/13/2015
Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated:  11/13/2015
NIH/National Cancer Institute
mi
from
Bethesda, MD
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated: 11/13/2015
NIH/National Cancer Institute
mi
from
Bethesda, MD
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated:  11/13/2015
Columbia University Medical Center
mi
from
New York, NY
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated: 11/13/2015
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated:  11/13/2015
Mary Babb Randolph Cancer Center
mi
from
Morgantown, WV
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated: 11/13/2015
Mary Babb Randolph Cancer Center
mi
from
Morgantown, WV
Click here to add this to my saved trials
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated:  11/13/2015
Princess Margaret Hospital
mi
from
Toronto,
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma
Status: Enrolling
Updated: 11/13/2015
Princess Margaret Hospital
mi
from
Toronto,
Click here to add this to my saved trials
An Open Label Extension Study of the Efficacy of MORAb-003
An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  11/13/2015
Sharp Memorial Hospital
mi
from
Chula Vista, CA
An Open Label Extension Study of the Efficacy of MORAb-003
An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 11/13/2015
Sharp Memorial Hospital
mi
from
Chula Vista, CA
Click here to add this to my saved trials
An Open Label Extension Study of the Efficacy of MORAb-003
An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  11/13/2015
South Texas Oncology and Hematology
mi
from
San Antonio, TX
An Open Label Extension Study of the Efficacy of MORAb-003
An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 11/13/2015
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Click here to add this to my saved trials
An Open Label Extension Study of the Efficacy of MORAb-003
An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated:  11/13/2015
Nationales Centrum fur Tumorerkrandungen
mi
from
Heidelberg,
An Open Label Extension Study of the Efficacy of MORAb-003
An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
Status: Enrolling
Updated: 11/13/2015
Nationales Centrum fur Tumorerkrandungen
mi
from
Heidelberg,
Click here to add this to my saved trials
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated:  11/14/2015
Cancer Institute at St. John's Hospital
mi
from
Springfield, IL
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated: 11/14/2015
Cancer Institute at St. John's Hospital
mi
from
Springfield, IL
Click here to add this to my saved trials
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated:  11/14/2015
Barnes-Jewish West County Hospital
mi
from
Saint Louis, MO
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated: 11/14/2015
Barnes-Jewish West County Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated:  11/14/2015
Siteman Cancer Center at Barnes-Jewish St. Peters Hospital - St. Peters
mi
from
Saint Peters, MO
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated: 11/14/2015
Siteman Cancer Center at Barnes-Jewish St. Peters Hospital - St. Peters
mi
from
Saint Peters, MO
Click here to add this to my saved trials
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated:  11/14/2015
Georgia Cancer Center for Excellence at Grady Memorial Hospital
mi
from
Atlanta, GA
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated: 11/14/2015
Georgia Cancer Center for Excellence at Grady Memorial Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated:  11/14/2015
Emory Crawford Long Hospital
mi
from
Atlanta, GA
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated: 11/14/2015
Emory Crawford Long Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated:  11/14/2015
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated: 11/14/2015
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated:  11/14/2015
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated: 11/14/2015
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated:  11/14/2015
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated: 11/14/2015
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated:  11/14/2015
MedCentral - Mansfield Hospital
mi
from
Mansfield, OH
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated: 11/14/2015
MedCentral - Mansfield Hospital
mi
from
Mansfield, OH
Click here to add this to my saved trials
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated:  11/14/2015
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study
Status: Enrolling
Updated: 11/14/2015
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas
A Phase I Study of Induction AMG 479 and Gemcitabine, Followed by AMG 479, Capecitabine, and 3D-Conformal Radiation Therapy (3D-CRT) With Subsequent Maintenance Therapy for Locally Advanced Pancreatic Cancer
Status: Enrolling
Updated:  11/14/2015
St. Joseph Hospital Regional Cancer Center - Orange
mi
from
Orange, CA
Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas
A Phase I Study of Induction AMG 479 and Gemcitabine, Followed by AMG 479, Capecitabine, and 3D-Conformal Radiation Therapy (3D-CRT) With Subsequent Maintenance Therapy for Locally Advanced Pancreatic Cancer
Status: Enrolling
Updated: 11/14/2015
St. Joseph Hospital Regional Cancer Center - Orange
mi
from
Orange, CA
Click here to add this to my saved trials
Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas
A Phase I Study of Induction AMG 479 and Gemcitabine, Followed by AMG 479, Capecitabine, and 3D-Conformal Radiation Therapy (3D-CRT) With Subsequent Maintenance Therapy for Locally Advanced Pancreatic Cancer
Status: Enrolling
Updated:  11/14/2015
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas
A Phase I Study of Induction AMG 479 and Gemcitabine, Followed by AMG 479, Capecitabine, and 3D-Conformal Radiation Therapy (3D-CRT) With Subsequent Maintenance Therapy for Locally Advanced Pancreatic Cancer
Status: Enrolling
Updated: 11/14/2015
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials